Outcomes of children and young adults with B-ALL following tisa-cel reinfusion

Kevin McNerney, MD, MSc, Johns Hopkins All Children's Hospital, St. Petersburg, FL, shares the results of a retrospective study evaluating the safety and efficacy of tisagenlecleucel (tisa-cel) reinfusion in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL). Overall, the study showed that second CAR-T infusions were well tolerated, allowed patients to achieve a complete remission (CR) or re-establish B-cell aplasia (BCA), and could be used as a bridge to transplant. However, most remissions were brief and BCA was limited. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.